Complement related kidney diseases: Recurrence after transplantation.

Area of Science:

• Nephrology
• Transplantation Immunology
• Complement System Biology

Background:

• Recurrence of primary renal diseases is a major cause of graft loss post-kidney transplantation.
• Atypical hemolytic uremic syndrome (HUS) and C3 glomerulopathy (formerly MPGN) are key culprits, linked to complement alternative pathway dysregulation.
• These complement abnormalities are often intrinsic and resistant to standard immunosuppression, leading to high recurrence rates.

Approach:

• Focus on early diagnosis of recurrence for timely therapeutic intervention.
• Exercise caution in transplanting patients with end-stage renal disease from C3 glomerulopathies or atypical HUS.
• Avoid living related donor transplantation due to potential shared genetic mutations.

Key Points:

• Complement pathway dysregulation (genetic or autoimmune) underlies high recurrence rates of HUS and C3 glomerulopathy post-transplant.
• Complement inhibitors, particularly eculizumab (anti-C5 convertase), represent a promising therapeutic strategy.
• Optimal dosing, duration, and cost-effectiveness of eculizumab require further investigation, with C3 convertase inhibitors as a potential alternative for resistant cases.

Conclusions:

• Early detection and cautious transplantation are crucial for patients with complement-mediated renal diseases.
• Complement inhibition offers a promising avenue for managing and preventing recurrence of these conditions.
• Ongoing research into complement inhibitors, including C3 convertase inhibitors, is vital for improving outcomes in kidney transplantation.